股票&市場分析
瀏覽 333萬
內容 5430
![](data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABgAAAAYCAYAAADgdz34AAAACXBIWXMAACE4AAAhOAFFljFgAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAD0SURBVHgB1ZVLDoIwEIan+FhzBLwBN9CufSSoe/UmchJ1bRQT2TfegCN4BFxLqK2JoTFI26kL/ZfD5PugM6QA/x6iazikbCOawrKEeD6hJ7BMo2B/ZoMWAVZVvOV01N+BRbymh+0CMuBwrSrl9pheFvAtQRTRnBRAXSTaGcgkCQt4WxwVgaCqmh2XkcBFYizASqwEGIm1wFaCEnyQ5Lc79FZi89Q+D/DJBVyF+X5X/SIHgXh7n3eef3j4qnEOcTSk2XsvZsi18NmYruv6bdfUCm4lwMCNBVi4kcAFLqPdIhe4ViAvHBe4VqBeOBi4ceQc4FfzANvOjGritIyVAAAAAElFTkSuQmCC)
Short term list and long term watch
short term: $Novan (NOVN.US)$ $Achieve Life (ACHV.US)$ $Yatra Online (YTRA.US)$
long term: $Ocugen (OCGN.US)$ heres why:
They can pretty much regenerate eyes.Yeah and have the patent
No competitors
With earnings coming up on the 6th and market cap has quadrupled in the last 4 days
Ah was a great average too!
Well they’ll beat earnings
I went through their balance sheet
Free cash flow up 85% YoY and for the current quarter + patent plus less outstanding shares plus they did a reverse split November 2019 so we won’t see that soon either.
Eps estimate is -.04 and has always been on point for the last 5 years HOWEVER 700m volume in 2 days is nothing to scoff at. So I believe they will beat earnings and even if they didn’t, it would be overshadowed by the patent
And they are a profitable penny stock in the biopharma sector and at its price, that’s a rarity
So I won’t be selling OCGN
$台積電 (TSM.US)$ and $Fastly (FSLY.US)$ will be long holds for obvious reasons as well so get them while they are on discount!
免責聲明:社區由Moomoo Technologies Inc.提供,僅用於教育目的。
更多信息
7
Me_Do_Stonk : 是啊,老兄
70121309 : 酷
OFFICER TRUTH 樓主 : 它正在跑!
D_Lay87 OFFICER TRUTH 樓主 : 最近是否有 OCGN 的新專利!?
Jtradev : 還在抓住奧庫根嗎?